Innoviva (INVA) Income from Non-Controlling Interests (2017 - 2022)
Innoviva (INVA) posted Income from Non-Controlling Interests of -$36.2 million for Q3 2022, down 277.06% on a QoQ basis from $20.4 million in Q2 2022, and down 153.45% year-over-year from $67.7 million in Q3 2021.
Innoviva (INVA) Income from Non-Controlling Interests (2017 - 2022) Analysis & Trends
Innoviva's Income from Non-Controlling Interests history runs 6 years deep, the most recent figure standing at -$36.2 million for Q3 2022.
- Quarterly Income from Non-Controlling Interests fell 153.45% year-over-year to -$36.2 million in Q3 2022, while the trailing twelve-month figure through Sep 2023 was -$36.2 million (down 148.87% YoY) and the FY2022 annual result came in at $6.3 million, down 70.68% from the prior year.
- Income from Non-Controlling Interests was -$36.2 million for Q3 2022 at Innoviva, down from $20.4 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $67.7 million in Q3 2021 and bottomed at -$36.2 million in Q3 2022.
- A 5-year average of $12.5 million and a median of $12.7 million in 2019 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2018 — Income from Non-Controlling Interests jumped 4128.68% — and 2022, when it plunged 153.45%.
- Innoviva's Income from Non-Controlling Interests stood at $5.5 million in 2018, then jumped by 118.39% to $11.9 million in 2019, then jumped by 77.23% to $21.1 million in 2020, then surged by 220.55% to $67.7 million in 2021, then plunged by 153.45% to -$36.2 million in 2022.
- Business Quant data shows INVA's Income from Non-Controlling Interests at -$36.2 million in Q3 2022, $20.4 million in Q2 2022, and $22.1 million in Q1 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Innoviva | 1.59 Bn | 983.20 Mn | 75.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -36.18 Mn |
| Jun 30, 2022 | 20.43 Mn |
| Mar 31, 2022 | 22.09 Mn |
| Sep 30, 2021 | 67.68 Mn |
| Jun 30, 2021 | 21.90 Mn |
| Mar 31, 2021 | 15.57 Mn |
| Dec 31, 2020 | 21.11 Mn |
| Sep 30, 2020 | 13.40 Mn |
| Jun 30, 2020 | 21.38 Mn |
| Mar 31, 2020 | 13.52 Mn |
| Dec 31, 2019 | 11.91 Mn |
| Sep 30, 2019 | 7.24 Mn |
| Jun 30, 2019 | 8.32 Mn |
| Mar 31, 2019 | 6.23 Mn |
| Dec 31, 2018 | 5.46 Mn |
| Sep 30, 2018 | 3.08 Mn |
| Jun 30, 2018 | 1.99 Mn |
| Mar 31, 2018 | 749,000.00 |
| Dec 31, 2017 | 129,000.00 |